130 related articles for article (PubMed ID: 28880012)
21. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
22. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
23. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
[TBL] [Abstract][Full Text] [Related]
24. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.
Jiang YQ; Zhang Z; Cai HR; Zhou H
Int J Clin Exp Pathol; 2015; 8(11):13785-94. PubMed ID: 26823692
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis.
Mao LJ; Zhang J; Liu N; Fan L; Yang DR; Xue BX; Shan YX; Zheng JN
Tumour Biol; 2015 Nov; 36(11):9073-81. PubMed ID: 26084613
[TBL] [Abstract][Full Text] [Related]
26. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
27. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
Gomez-Gutierrez JG; Nitz J; Sharma R; Wechman SL; Riedinger E; Martinez-Jaramillo E; Sam Zhou H; McMasters KM
Virology; 2016 Jan; 487():249-59. PubMed ID: 26561948
[TBL] [Abstract][Full Text] [Related]
28. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
29. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
30. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
31. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic reovirus effectively targets breast cancer stem cells.
Marcato P; Dean CA; Giacomantonio CA; Lee PW
Mol Ther; 2009 Jun; 17(6):972-9. PubMed ID: 19293772
[TBL] [Abstract][Full Text] [Related]
33. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
34. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer.
Huang F; Wang BR; Wu YQ; Wang FC; Zhang J; Wang YG
World J Gastroenterol; 2016 Sep; 22(35):7999-8009. PubMed ID: 27672294
[TBL] [Abstract][Full Text] [Related]
36. Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.
Schenk E; Essand M; Kraaij R; Adamson R; Maitland NJ; Bangma CH
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):7-15. PubMed ID: 24649837
[TBL] [Abstract][Full Text] [Related]
37. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
[TBL] [Abstract][Full Text] [Related]
38. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
39. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
40. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK
Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]